Tucidinostat

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Tucidinostat
Accession Number
DB06334
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • Chidamide
External IDs
CS-055 / CS055 / HBI-8000
Categories
UNII
87CIC980Y0
CAS number
1616493-44-7
Weight
Average: 390.418
Monoisotopic: 390.149204031
Chemical Formula
C22H19FN4O2
InChI Key
SZMJVTADHFNAIS-BJMVGYQFSA-N
InChI
InChI=1S/C22H19FN4O2/c23-18-8-9-20(19(24)12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)/b10-5+
IUPAC Name
N-(2-amino-4-fluorophenyl)-4-{[(2E)-3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide
SMILES
NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\C=C\C2=CN=CC=C2)C=C1

Pharmacology

Indication

Investigated for use/treatment in cancer/tumors (unspecified).

Pharmacodynamics
Not Available
Mechanism of action

Chidamide is an orally bioavailable histone deacetylase (HDAC) inhibitor derived from the benzamide class. Histone deacetylase inhibitors are a class of cancer drugs that induce selective regulation of gene expression in cancer cells. [HUYA Biosciences Press Release]

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbexinostatThe risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Abexinostat.
AcebutololThe risk or severity of QTc prolongation can be increased when Acebutolol is combined with Tucidinostat.
AceprometazineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Tucidinostat.
AcetyldigoxinThe risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Tucidinostat.
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Tucidinostat.
AdenosineThe risk or severity of QTc prolongation can be increased when Adenosine is combined with Tucidinostat.
AjmalineThe risk or severity of QTc prolongation can be increased when Ajmaline is combined with Tucidinostat.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Tucidinostat.
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with Tucidinostat.
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Tucidinostat.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
48058599
ChEBI
135918
ChEMBL
CHEMBL3621988

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
1CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
1WithdrawnTreatmentCancer, Breast1
1, 2CompletedTreatmentChronic Infection With HIV1
1, 2Not Yet RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2RecruitingTreatmentSafety and Efficacy1
1, 2RecruitingTreatmentT Cell Non-Hodgkin's Lymphoma1
2Active Not RecruitingTreatmentAdult T-Cell Lymphoma (ATL)1
2Active Not RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Not Yet RecruitingTreatmentExperimental1
2Not Yet RecruitingTreatmentExperimental Tumor2
2Not Yet RecruitingTreatmentExtranodal NK/T-cell Lymphoma1
2Not Yet RecruitingTreatmentLeukemia, Acute / Smith-Magenis Syndrome1
2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Not Yet RecruitingTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
2Not Yet RecruitingTreatmentMultiple Myeloma (MM)1
2Not Yet RecruitingTreatmentRelapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAdenocystic Carcinoma1
2RecruitingTreatmentAngioimmunoblastic T-Cell Lymphoma2
2RecruitingTreatmentDouble-hit Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Peripheral T Cell Lymphoma (PTCL)1
2RecruitingTreatmentExperimental Tumor1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)3
2RecruitingTreatmentMalignant Lymphomas1
2RecruitingTreatmentNatural Killer/T-Cell Lymphoma, Nasal and Nasal-Type1
2RecruitingTreatmentPeripheral T Cell Lymphoma (PTCL)2
2RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
2, 3Active Not RecruitingTreatmentChronic Infection With HIV1
2, 3RecruitingTreatmentAdult Acute Lymphoblastic Leukemia / Adult Lymphoblastic Lymphoma / Leukaemia, Lymphoblastic / Leukemia, Acute / Leukemia, T Cell / Leukemias / Lymphoma, Lymphoblastic1
2, 3RecruitingTreatmentLeukaemia, Lymphoblastic / Leukemia, Acute / Leukemia, B-Cell / Leukemias1
2, 3RecruitingTreatmentLeukaemia, Lymphoblastic / Leukemia, Acute / Leukemia, T Cell1
3Active Not RecruitingTreatmentCancer, Breast1
3Not Yet RecruitingTreatmentPeripheral T Cell Lymphoma (PTCL)1
Not AvailableRecruitingTreatmentPeripheral T Cell Lymphoma (PTCL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00236 mg/mLALOGPS
logP2.55ALOGPS
logP2.47ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)13.67ChemAxon
pKa (Strongest Basic)4.84ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area97.11 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity112.68 m3·mol-1ChemAxon
Polarizability41.27 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Benzanilides
Alternative Parents
Benzamides / Benzoyl derivatives / Aniline and substituted anilines / Fluorobenzenes / Pyridines and derivatives / Aryl fluorides / Heteroaromatic compounds / Secondary carboxylic acid amides / Amino acids and derivatives / Azacyclic compounds
show 5 more
Substituents
Benzanilide / Benzamide / Benzoic acid or derivatives / Benzoyl / Aniline or substituted anilines / Fluorobenzene / Halobenzene / Aryl fluoride / Aryl halide / Pyridine
show 19 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on March 19, 2008 10:24 / Updated on June 04, 2019 06:23